AUSTRALIA —In a groundbreaking study, researchers at the University of South Australia (UniSA) have unveiled a cutting-edge discovery that could transform the landscape of prostate cancer diagnosis and treatment.
Traditionally, the Gleason score served as the cornerstone for assessing prostate cancer grade. Yet, due to its subjective nature when performed by humans, discrepancies between observers could occur, impacting treatment decisions.
In 2020 alone, prostate cancer diagnoses surpassed 1.4 million, with an estimated 375,304 fatalities reported.
Survival rates hinged on various factors, including cancer stage, grade, age, overall health, and treatment response.
However, the accuracy of current screening methods remains a concern, often leading to unnecessary biopsies and treatments.
In the study, the researchers delved into alterations in cell biology associated with different grades of prostate cancer.
By identifying three novel biomarkers, they aim to revolutionize patient management and enhance treatment outcomes for millions of men affected by this devastating disease.
They honed in on the endosome-lysosome system, an integral part of cancer development, and examined three proteins—Appl1, Sortilin, and Syndecan-1—that hold potential as reliable biomarkers.
Notably, these protein biomarkers showcased the ability to unveil previously unseen features in tissue samples compared to conventional staining techniques.
To validate their findings, tissue samples generously donated by 114 men who had undergone radical prostatectomy between 2006 and 2014 were meticulously analyzed.
The results offered promising insights into the potential of these biomarkers to differentiate aggressive cases from less threatening ones, aiding clinicians in making critical decisions regarding treatment urgency.
While this breakthrough was undoubtedly a significant step forward, the journey to more accurate prostate cancer diagnosis does not stop there.
Enter microRNAs, the latest revelation in the realm of biomarkers. These minuscule RNA molecules regulate gene expression and have shown promise in pinpointing dysregulated patterns associated with prostate cancer cells.
The ability to detect these specific microRNAs in blood and urine samples opened up a world of possibilities for improved screening and diagnosis.
The biomarkers are remarkably sensitive and specific in accurately visualizing the progress of cancer and confirming its grade.
This discovery has led to the commercial development of a test designed to determine how advanced and aggressive the cancer is and whether immediate treatment is needed.
Excitingly, the Australian company Envision Sciences joined forces with UniSA, funding and translating this groundbreaking technology.
They have already signed a commercialization agreement with Quest Diagnostics, the largest tissue diagnostic pathology company in the US, to bring the technology into clinical practice.
Pending success in the US, it is expected that clinical trials using this innovative approach will commence in Australia.
The study’s publication in the prestigious journal Cancers solidifies its significance in the scientific community, raising hopes for a new era in prostate cancer diagnosis and patient care.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
